Orexo Ab Stock Fundamentals
| ORXOF Stock | USD 1.08 0.00 0.00% |
Orexo AB fundamentals help investors to digest information that contributes to Orexo AB's financial success or failures. It also enables traders to predict the movement of Orexo OTC Stock. The fundamental analysis module provides a way to measure Orexo AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orexo AB otc stock.
Orexo |
Orexo AB OTC Stock Return On Equity Analysis
Orexo AB's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Orexo AB Return On Equity | -0.65 |
Most of Orexo AB's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orexo AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Orexo AB has a Return On Equity of -0.6535. This is 97.27% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 110.81% higher than that of the company.
Orexo AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Orexo AB's current stock value. Our valuation model uses many indicators to compare Orexo AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orexo AB competition to find correlations between indicators driving Orexo AB's intrinsic value. More Info.Orexo AB is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Orexo AB's earnings, one of the primary drivers of an investment's value.Orexo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orexo AB's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orexo AB could also be used in its relative valuation, which is a method of valuing Orexo AB by comparing valuation metrics of similar companies.Orexo AB is currently under evaluation in return on equity category among its peers.
Orexo Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.0965 | |||
| Profit Margin | (0.28) % | |||
| Current Valuation | 76.98 M | |||
| Shares Outstanding | 34.35 M | |||
| Shares Owned By Insiders | 17.29 % | |||
| Shares Owned By Institutions | 42.78 % | |||
| Price To Earning | 58.66 X | |||
| Price To Book | 2.02 X | |||
| Price To Sales | 0.99 X | |||
| Revenue | 565 M | |||
| Gross Profit | 521.7 M | |||
| EBITDA | (141.3 M) | |||
| Net Income | (223.5 M) | |||
| Cash And Equivalents | 45.61 M | |||
| Cash Per Share | 1.32 X | |||
| Total Debt | 492.3 M | |||
| Debt To Equity | 1.76 % | |||
| Current Ratio | 2.05 X | |||
| Book Value Per Share | 1.07 X | |||
| Cash Flow From Operations | (229 M) | |||
| Number Of Employees | 126 | |||
| Beta | 0.72 | |||
| Market Capitalization | 58.7 M | |||
| Total Asset | 1.27 B | |||
| Working Capital | 604 M | |||
| Current Asset | 907 M | |||
| Current Liabilities | 303 M | |||
| Net Asset | 1.27 B |
About Orexo AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orexo AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orexo AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orexo AB based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. Orexo Ab is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Orexo OTC Stock
Orexo AB financial ratios help investors to determine whether Orexo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Orexo with respect to the benefits of owning Orexo AB security.